Hyperbaric Oxygen Therapy Counters Oxidative Stress/Inflammation-Driven Symptoms in Long COVID-19 Patients: Preliminary Outcomes

Long COVID-19 patients show systemic inflammation and persistent symptoms such as fatigue and malaise, profoundly affecting their quality of life. Since improving oxygenation can oppose inflammation at multiple tissue levels, we hypothesized that hyperbaric oxygen therapy (HBOT) could arrest inflamm...

Full description

Saved in:
Bibliographic Details
Published in:Metabolites 2023-09, Vol.13 (10), p.1032
Main Authors: Mrakic-Sposta, Simona, Vezzoli, Alessandra, Garetto, Giacomo, Paganini, Matteo, Camporesi, Enrico, Giacon, Tommaso Antonio, Dellanoce, Cinzia, Agrimi, Jacopo, Bosco, Gerardo
Format: Article
Language:English
Subjects:
Acids
Antioxidants
Asymptomatic
Biomarkers
Comorbidity
Control
COVID-19
DNA damage
HBOT
Health aspects
Hearing loss
Hyperbaric oxygen therapy
Hyperbaric oxygenation
Infections
Inflammation
Lipid peroxidation
long COVID-19
Metabolites
Nitrates
Osteomyelitis
Oxidative stress
Oxygen therapy
Patients
Physiological aspects
Pilot projects
Quality of life
Reactive oxygen species
Saliva
Spectrum analysis
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long COVID-19 patients show systemic inflammation and persistent symptoms such as fatigue and malaise, profoundly affecting their quality of life. Since improving oxygenation can oppose inflammation at multiple tissue levels, we hypothesized that hyperbaric oxygen therapy (HBOT) could arrest inflammation progression and thus relieve symptoms of COVID-19. We evaluated oxy-inflammation biomarkers in long COVID-19 subjects treated with HBOT and monitored with non-invasive methods. Five subjects (two athletes and three patients with other comorbidities) were assigned to receive HBOT: 100% inspired O2 at 2.4 ATA in a multiplace hyperbaric chamber for 90 min (three athletes: 15 HBOT × 5 days/wk for 3 weeks; two patients affected by Idiopathic Sudden Sensorineural Hearing Loss: 30 HBOT × 5 days/wk for 6 weeks; and one patient with osteomyelitis: 30 HBOT × 5 days/wk for week for 6 weeks and, after a 30-day break, followed by a second cycle of 20 HBOT). Using saliva and/or urine samples, reactive oxygen species (ROS), antioxidant capacity, cytokines, lipids peroxidation, DNA damage, and renal status were assessed at T1_pre (basal level) and at T2_pre (basal level after treatment), and the results showed attenuated ROS production, lipid peroxidation, DNA damage, NO metabolites, and inflammation biomarker levels, especially in the athletes post-treatment. Thus, HBOT may represent an alternative non-invasive method for treating long COVID-19-induced long-lasting manifestations of oxy-inflammation.
ISSN:2218-1989
2218-1989
DOI:10.3390/metabo13101032